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Abstract: Cardiovascular diseases are directly affected by arterial hypertension. When associ-
ated with diabetes mellitus, the potential deleterious effects are well ampliﬁed. Both conditions 
play a central role in the pathogenesis of coronary artery disease, heart failure, stroke, and renal 
insufﬁciency. Prevalence of hypertension is much higher among diabetic than non-diabetic 
patients, and the hypertensive patient is more likely to develop type 2 diabetes. Current inter-
national guidelines recommend aggressive reductions in blood pressure (BP) in hypertensive 
patients with additional risk factors, including cardiovascular risk factors, and emphasize the 
relevance of intensive reduction in patients with diabetes mellitus; a goal of 130/80 mm Hg 
is required. To achieve BP target a combination of antihypertensives will be needed, and the 
use of long-acting drugs that are able to provide 24-hour efﬁcacy with a once-daily dosing 
confers the noteworthy advantages of compliance improvement and BP variation lessening. 
Lower dosages of the individual treatments of the combination therapy can be administered 
for the same antihypertensive efﬁciency as that attained with high dosages of monotherapy. 
Angiotensin-converting enzyme inhibitors and calcium-channel blockers  as a combination have 
theoretically compelling advantages for vessel homeostasis. Trandolapril/verapamil sustained 
release combination has showed beneﬁcial effects on cardiac and renal systems as well as its 
antihypertensive efﬁcacy, with no metabolic disturbances. This combination can be considered 
as an effective therapy for the diabetic hypertensive population.
Keywords: hypertension, trandolapril, verapamil, diabetes, renin-angiotensin system, com-
bination therapy 
Introduction
Prevalence of hypertension in the diabetic population is 1.5–3 times higher than in the 
non-diabetic population after adjusting for age and weight (HDS 1993). Extensive evi-
dence indicates that in diabetic individuals, arterial hypertension greatly contributes to an 
increase in the risk of atherosclerosis (Sowers et al 1994; Adler et al 2000). People with 
type 2 diabetes have a greater incidence of cardiovascular (CV) disease, cerebrovascular 
disease, and renal disease than the general population (Kannel and McGee 1979; Knuiman 
et al 1986; Klein 1995). Epidemiological studies suggest that relative hyperglycemia 
accounts for part but not all of the increased CV risk. Raised BP is a major risk factor for 
myocardial infarction and stroke in people with and without diabetes (Hanefeld et al 1996; 
Lehto et al 1997). A difference of 5 mm Hg in either systolic blood pressure (SBP) or 
diastolic blood pressure (DBP) accounts for an increase in cardiovascular events or death 
of 20%–30% in diabetic patients (McMahon et al 1990). A strict BP control is critical 
in diabetic people in order to prevent organ damage due to the rising cardiovascular risk 
that accompanies small BP elevations (Vasan et al 2001). It is accepted that BP values 
above 130/85 mm Hg, or even 130/80 mm Hg, deserve to be treated based on the existing 
epidemiological data showing reduced cardiovascular risk at SBP less than 130 mm Hg Vascular Health and Risk Management 2007:3(1) 78
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(Bakris et al 2000; JNC 2003). Nevertheless, it has been sug-
gested that physicians accept an elevated SBP in their patients 
that could facilitate a passive attitude in type 2 diabetic patients 
(Oliveira et al 2002). Antihypertensive therapy has been shown 
to be of great value in order to diminish the cardiovascular, 
renal, and ocular complications of diabetes (Schrier et al 2002; 
Zanchetti and Ruilope 2002). The metabolic alterations that 
are likely to be present in diabetic hypertensive patients can 
concomitantly accelerate or precipitate CV complications. 
Therefore, the metabolic effects and associated consequences 
of antihypertensive treatments on insulin resistance, glycemia, 
lipids, or potassium homeostasis must be considered in choos-
ing a therapeutic regimen (Teuscher and Wiedmann 1997). The 
attention paid to identifying the optimal antihypertensive agent 
for type 2 diabetics may appear rather questionable in view of 
the need for multiple drugs in order to lower BP to the difﬁcult 
goal of <130/80 mm Hg. The positive effects are enhanced 
by the presence of an angiotensin converting enzyme (ACE) 
inhibitor  or an angiotensin receptor blocker (ARB) when 
the kidney is damaged (Ravid et al 1993). The issue is not 
that clear for cardiovascular complications where the beneﬁt 
seems to depend on the drop in BP and not so much the type 
of therapy employed. Moreover, the need for a combination 
of different antihypertensive agents to achieve the BP goal 
has been shown in the great majority of participants with 
hypertension in clinical trials (Hilleman et al 1999; Ruilope 
et al 1999). According to current international guidelines, in 
most hypertensive patients, therapy must initiated gradually, 
and target BP values achieved progressively through several 
weeks. To reach target BP, it is likely that a large proportion of 
patients will require combination therapy with more than one 
agent (ESH–ESC 2003). Combining two drugs may reduce 
BP by several mechanisms of action and obtain additive or 
strengthened effects. By using low doses of drugs, side-effects 
are minimized and patient compliance improves. 
ACE inhibitors and calcium-channel blockers (CCB) have 
favorable hemodynamic proﬁles and both have beneﬁcial 
cardiovascular effects with no signiﬁcant adverse metabolic 
effects (Cifkova et al 2000; PROCOPA Study Group 2002). 
A combination of these treatments offers beneﬁts over every 
drug on monotherapy and may potentially be better than other 
combined regimens. 
Target organ damage protection  
in hypertensive diabetics
Various randomized controlled trials comparing antihy-
pertensive regimens that included both patients with and 
without type 2 diabetes helped explain the inﬂuence on 
cardiovascular risk of having type 2 diabetes in association 
with hypertension. Among placebo-treated patients in two 
trials on elderly patients with isolated systolic hypertension 
(the Systolic Hypertension in the Elderly Program [SHEP] 
and the Systolic Hypertension in Europe trial [SystEur]), the 
incidence of major cardiovascular events, and the relative 
risks for coronary events, stroke, and all deaths was higher in 
the presence than in the absence of diabetes (Curb et al 1996; 
Tuomilehto et al 1999). With regard to diastolic BP, the   
Hypertension Optimal Treatment (HOT) study showed a 51% 
reduction in cardiovascular events in diabetic participants 
randomized to a target DBP of 80 mm Hg when compared 
with a group randomized to a target of 90 mm Hg (Hansson 
et al 1998). In the Heart Outcomes Prevention Evaluation 
study (HOPE) incidence of major cardiovascular events was 
1.2 times higher in diabetic than in non-diabetic subjects,   
although only 46.8% of subjects also had hypertension 
(HOPE 2000b). However, in this study, when diabetes 
was linked to another powerful predictor of cardiovascular 
events, such as impaired renal function, incidence of car-
diovascular events among placebo-controlled patients was 
almost twice as high that in non-diabetic subjects with a 
comparable reduction in renal function (Ruilope et al 2001). 
Nevertheless, the high cardiovascular risk demonstrated in 
type 2 diabetics is not just as a result of the high prevalence 
of hypertension among these patients. For instance, in the 
Appropriate Blood Pressure Control in Diabetes study 
(ABCD-NT), which enrolled diabetic patients with blood 
pressure <140/90 mm Hg, subjects in the placebo arm with 
an average blood pressure of 137/81 mm Hg had an incidence 
of major cardiovascular events of approximately 16% in 5 
years (Schrier et al 2002).
Further evidence of the close association between type 
2 diabetes and renal damage has been shown in a number of 
trials. Among the placebo-treated elderly hypertensives of 
the SystEur trial, incidence of proteinuria was much higher 
in diabetic than in non-diabetic subjects (58.0 vs 15.1 cases 
per 1000 patient years). In the HOT study, incidence of 
renal dysfunction (deﬁned as an increase of baseline cre-
atinine ≥30% with ﬁnal values >176 µmol/L or 2.0 mg/dL) 
was rare, but was 45% more frequent in diabetic than in 
non-diabetic patients. Also, in the MICRO-HOPE substudy 
(HOPE 2000a), incidence of clinical proteinuria among 
diabetic patients receiving placebo was high (8.4% during 
4.5 years) and, in further studies (Brenner et al 2001; Lewis 
et al 2001) on type 2 diabetic subjects with hypertension and Vascular Health and Risk Management 2007:3(1) 79
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nephropathy (the Irbesartan Diabetic Nephropathy Trial, 
IDNT, and the Reduction of Endpoints in NIDDM with 
the Angiotensin II Antagonist Losartan study, RENAAL), 
patients randomized to normal treatment plus placebo had a 
very high incidence of doubling of baseline serum creatinine, 
end stage renal disease, and death (cumulative endpoint   
incidence of 39% during 3 years in the IDNT and 47% dur-
ing 3.4 years in the RENAAL). In the diabetic hypertensives 
of the Irbesartan Microalbuminuria study (IRMA-2) with 
milder initial nephropathy (microalbuminuria only), 15% of 
the placebo-treated patients developed proteinuria in 2 years 
(Parving et al 2001). 
The positive effects are enhanced by the presence 
of an ACE inhibitor or an angiotensin receptor blocker 
when the kidney is damaged. This beneﬁt has been tested 
for preventing the development of microalbuminuria in 
hypertensive diabetics. The multicenter, double-blind, 
randomized Bergamo Nephrologic Diabetes Complications 
Trial (BENEDICT) was designed to assess whether ACE 
inhibitors and non-dihydropyridine CCBs, alone or in 
combination, prevent microalbuminuria in subjects with 
hypertension, type 2 diabetes, and normal urinary albumin 
excretion (Ruggenenti et al 2004). The primary endpoint 
was the development of persistent microalbuminuria (over-
night albumin excretion, ≥20 µg per minute at 2 consecutive 
visits). More than 1200 subjects were randomized to receive 
at least 3 years of treatment with trandolapril (2 mg/day) 
plus verapamil sustained-release (TV SR) formulation (180 
mg/day), trandolapril alone (2 mg/day), verapamil alone 
(sustained-release formulation, 240 mg/day), or placebo. 
The main results showed that TV and trandolapril alone 
signiﬁcantly decreased the incidence of microalbuminuria 
to a similar extent. 
Metabolic control and 
antihypertensive treatment 
The widely described association between hypertension and 
diabetes is promoted by interplay of hereditary and acquired 
disturbances. Up to 50% of diabetic patients become hyper-
tensive, whereas patients with essential hypertension are prone 
to develop type 2 diabetes. Treatment-associated metabolic 
alterations are crucial in hypertensive diabetic patients. Con-
sequently, the optimal drug for hypertensive diabetic patients 
should not only lower blood pressure, but also concomitantly 
improve, or at least not worsen, associated risk factors (Jarrett 
et al 1994). The need for a combination of different antihy-
pertensive agents to achieve the BP goal has been shown 
in the great majority of hypertensives. An emerging body 
of evidence in mixed populations suggests that ﬁxed-dose 
combination therapy is more effective than commonly used 
monotherapies in achieving target BP goals. Among them 
the combination of an ACE inhibitor and a CCB has widely 
proven in clinical practice in diabetic patients (Schneider et al 
1996). Fixed combinations have to be considered within the 
new strategies developed to increase the percentage of diabetic 
patients achieving an adequate BP control. The ultimate goal 
of treatment is to prevent diabetes and hypertension without 
detrimental metabolic side-effects.
In a subgroup of patients, lifestyle modiﬁcations might 
prevent or delay the onset of hypertension and diabetes. In 
contrast to some proven prognostic beneﬁt of thiazide-type 
diuretics and/or β-blockers in non-diabetic patients with 
uncomplicated essential hypertension, the influence of 
these agents on the prognosis of diabetic patients may be 
deleterious. The TRAVEND study was designed to com-
pare, at equal BP reduction, the effect of TV SR 2/180 mg 
and enalapril/hydroclorothiazide (EH) 20/12.5 mg during a   
6-month period on metabolic control and albuminuria in 
type 2 diabetic hypertensive patients with albuminuria   
(Fernandez et al 2001). Overall BP was signiﬁcantly reduced 
and albuminuria signiﬁcantly decreased, both without signiﬁ-
cant differences between treatments. Glycated hemoglobin 
was not modiﬁed on TV, but increased on EH. At the end 
of the study, a blood glucose <126 mg/dL was attained in 
72.7% of the TV group (improving in 29.5% and worsen-
ing in 6.8% of patients [p = 0.021]) and in 50% of the EH 
group, 13.6% of patients improved and 11.4% worsened (p = 
1.000). Similarly, in a 3-month randomized, controlled trial, 
there were no signiﬁcant changes from baseline in plasma 
glycated hemoglobin, fasting plasma glucose, insulin levels, 
or the insulin sensitivity index in recipients of TV (mean 
dosage 1.6/180 mg/day). However, inpatients treated with 
atenolol/chlortalidone (mean dosage 71/18 mg/day), there 
was a reduction in the insulin sensitivity index compared with 
baseline. Lipid indices did not change during TV treatment. 
In contrast, serum total triglyceride levels increased and HDL 
cholesterol decreased in atenolol/chlortalidone recipients. 
ACE inhibitors (or ARB) and/or certain calcium antagonists 
have emerged as the preferred antihypertensive agents in dia-
betic patients. Although the comparative inﬂuence of differ-
ent calcium antagonists on important factors other than blood 
pressure is insufﬁciently delineated, verapamil or diltiazem 
seem to be preferable to dihydropyridines, because the latter 
may be less effective in reducing proteinuria. Furthermore, Vascular Health and Risk Management 2007:3(1) 80
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certain CCB/ACE inhibitor combinations, such as TV, that 
provide supplementary antihypertensive efﬁcacy, metabolic 
neutrality, and probably also synergistic nephroprotection, 
may become an attractive therapeutic approach to the diabetic 
population with hypertension and/or renal or other target-
organ disease (Bakris et al 1998). The main effects of both 
drugs are summarized in Table 1. 
Cardiovascular effects of TV
Hypertension and diabetes play central roles in the patho-
genesis of coronary heart disease, congestive heart failure, 
stroke, and renal failure. The main goal of the treatment 
should be to reduce morbidity and mortality, and decrease 
collateral effects. Aggressive reductions in BP are recom-
mended in hypertensive diabetic patients and achievement 
of <30/80 mm Hg is required to diminish global CV risk. 
The results of recent randomized trials on diabetic patients 
with major cardiovascular events, cardiovascular death, 
and total mortality as primary endpoints, in which more or 
less intensive BP lowering was tested or an active regimen 
was compared with placebo, assert that more intensive BP 
lowering is beneﬁcial in reducing the aggregate of major car-
diovascular events in type 2 diabetic patients. The PRADID 
study (Ruilope et al 2004) was a multicentric, double-blind, 
placebo-controlled study with a 16-week follow-up includ-
ing 438 previously untreated type 2 diabetics; the primary 
endpoint was to attain the recommended guideline goals 
of a systolic and diastolic BP. Patients were randomized to 
receive a TV ﬁxed dose of 180/2 mg, versus trandolapril 
2 mg, versus placebo. Both active groups were more effec-
tive than placebo in decreasing SBP and DBP. At the end 
of the study, 36.5% in the trandolapril group, 37.8% in the 
TV group, and 14.9% placebo (p = 0.009) had attained the 
primary endpoint. Control rate on the DBP was signiﬁcantly 
higher in the TV (88.8%), when compared with trandolapril 
(79.1%) or placebo (63.5%) (P = 0.002). Therefore, these 
results support the concept that antihypertensive treatment 
is more effective than placebo for BP control in previously 
untreated type 2 diabetic patients, and a TV ﬁxed-dose com-
bination could be more effective than trandolapril alone for 
preventing increases in DPB. The Combination of an ACE 
inhibitor and a CCB should be safely used in clinical practice 
for diabetic patients. The combination of an ACE inhibitor 
such as trandolapril, and a CCB such as verapamil, is very 
attractive due to their common ability to reduce peripheral 
vasoconstriction without distressing cardiac output, and to 
facilitate salt and water excretion by different mechanisms 
(Muijsers et al 2002). The use of two long-acting drugs 
provides control over a 24-hour period. This quality can 
contribute to a increased therapy adherence, minimization of 
BP variation, and, therefore, a higher protection against the 
risk of major CV events and the development of target organ 
damage. TV combination can be particularly beneﬁcial in 
hypertensive diabetic patients with cardiac or renal disease. 
Data from a number of studies point to signiﬁcant reductions 
in albuminuria in patients receiving TV and, interestingly, 
Bakris et al (2004) reported that the reduction appears to 
be independent of the BP-lowering effect. As mentioned 
above, the BENEDICT study has reported a beneﬁcial 
primary prevention of renal disease as microalbuminuria, 
in hypertensive diabetics (Ruggenenti et al 2004) . 
Moreover, this combination has demonstrated other CV 
beneﬁts in a limited number of randomized trials by reduc-
ing left ventricular hypertrophy, total peripheral resistance, 
and pulse wave velocity. The INternational VErapamil SR- 
Trandolapril study (INVEST) was designed to compare mor-
bidity and mortality in hypertensives with coronary artery 
disease treated with a CCB or a non-CCB (atenolol-based) 
Table 1 Summary of the clinical properties of trandolapril and verapamil in hypertensives 
Trandolapril  Verapamil
Neutral effect on heart rate  Moderating effect on heart rate
Reduces the breakdown of bradykinin  Inhibits sympathetic nervous cell activation
Reduces blood pressure by inhibiting the renin-angiotensin system.   Reduces blood pressure by inhibiting the calcium ﬂow across  
Induces decreased vasopressor activity, aldosterone secretion.   the vascular and cardiac smooth muscle cells.
Reduces left ventricle hypertrophy  Reduces left ventricle hypertrophy
Neutral effect on lipid metabolism and neutral or beneﬁcial effect  Neutral effect on glucose and lipid metabolism 
on insulin sensitivity
Decreases water and sodium retention. Induces a modest   Neutral effect on water and ion control 
increase in kaliemia
Improves elastic properties of large arteriesVascular Health and Risk Management 2007:3(1) 81
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regimen (Pepine et al 2003). Diabetic patients comprised 6400 
out of 22 576 (28.3%) at entry. During a mean follow-up of 2.7 
years, 913 diabetic patients suffered a primary outcome event 
(a composite of ﬁrst occurrence of all-cause death, non-fatal 
myocardial infarction, or non-fatal stroke), with no signiﬁcant 
difference between treatment strategies. Risk for the primary 
outcome increased with presence of baseline heart failure, renal 
impairment, age, previous stroke/transient ischemic attack, 
previous myocardial infarction, peripheral vascular disease, or 
smoking. High SBP and DBP during follow-up also were asso-
ciated with increased risk, as were low DBP. Antihypertensive 
treatment with a verapamil SR or atenolol strategy resulted 
in similar rates of cardiovascular outcomes in coronary artery 
disease (CAD) patients with diabetes. Therefore, a verapamil 
SR-based antihypertensive treatment strategy can be consid-
ered as an alternative to a ß-blocker-based strategy in adults 
with CAD and diabetes (Muijsers et al 2002).
In conclusion, TV SR combination is an effective treat-
ment for hypertensive diabetics.
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